G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 535.8 INR -1.11% Market Closed
Market Cap: 433.4B INR
Have any thoughts about
Glenmark Pharmaceuticals Ltd?
Write Note

Glenmark Pharmaceuticals Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Glenmark Pharmaceuticals Ltd
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Cash from Financing Activities
-â‚ą37B
CAGR 3-Years
-99%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash from Financing Activities
â‚ą30.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash from Financing Activities
-â‚ą16.8B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash from Financing Activities
-â‚ą58.9B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash from Financing Activities
-â‚ą26.5B
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Cash from Financing Activities
â‚ą52.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Pharmaceuticals Ltd
Glance View

Market Cap
433.4B INR
Industry
Pharmaceuticals

Glenmark Pharmaceuticals Ltd., founded in 1977 by Gracias Saldanha, has crafted its journey from a single-product company to a noteworthy player in the global pharmaceutical landscape. Headquartered in Mumbai, India, its growth has been driven by a formidable strategy of focusing on both generics and novel drug discovery. In the fiercely competitive world of pharmaceuticals, Glenmark carved its niche by building a diverse product portfolio that spans across dermatology, respiratory, and oncology segments, among others. The company’s nuanced understanding of therapeutic areas and its pursuit of complex generics have empowered it to not only tap into established markets but also venture into emerging ones across 80 countries. This international strategy, combined with robust research and development infrastructure, underscores how Glenmark leverages scientific innovation to ensure steady revenue streams. At the heart of Glenmark's operations lies its commitment to research-driven growth. The company allocates significant resources to its R&D initiatives, manifesting in state-of-the-art facilities across India, Switzerland, and the U.S. Through these centers, Glenmark focuses on the development of differentiated generic medicines and the discovery of innovative therapeutic molecules. The synergy between its generic and innovative drug segments enables Glenmark to sustain profitability by capitalizing on patent expiries while simultaneously pioneering novel drug therapies. This dual approach not only helps the company secure a competitive position in the pharmaceutical market but also fuels its earnings through a balanced mix of volume-driven sales and premium pricing of differentiated products.

GLENMARK Intrinsic Value
1 053.31 INR
Overvaluation 31%
Intrinsic Value
Price
G

See Also

What is Glenmark Pharmaceuticals Ltd's Cash from Financing Activities?
Cash from Financing Activities
-37B INR

Based on the financial report for Sep 30, 2024, Glenmark Pharmaceuticals Ltd's Cash from Financing Activities amounts to -37B INR.

What is Glenmark Pharmaceuticals Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-99%

The average annual Cash from Financing Activities growth rates for Glenmark Pharmaceuticals Ltd have been -99% over the past three years .

Back to Top